经导管二尖瓣修复术与30天及1年生活质量结局的关联:TVT注册分析
该队列研究基于STS/ACC TVT注册,纳入2013–2017年美国217家医院接受TMVR的重度二尖瓣反流患者,分析KCCQ-OS在30天和1年的变化。1年时54.2%存活且健康良好。
要点
- TMVR后30天KCCQ-OS平均提高24.8分,临床意义显著。
- 30天至1年健康状态保持稳定,无进一步显著变化。
- 房颤、起搏器、严重肺病、家庭氧疗及基线KCCQ较低与30天评分较低独立相关。
核心结论
- 在美国临床实践接受TMVR的患者中,术前健康状态受损,30天内改善,存活且有数据者至1年保持稳定。
- 尽管长期死亡率仍高,多数存活患者症状、功能状态和生活质量改善,患者因素间差异不大。
研究设计与样本
- 回顾性队列研究,使用STS/ACC TVT注册数据,纳入2013–2017年美国217家医院接受TMVR的重度二尖瓣反流患者。
- 主要结局为30天和1年KCCQ-OS变化,采用多变量线性回归及广义估计方程分析30天相关因素。
主要发现
- 30天至1年KCCQ评分保持稳定,无进一步显著升高或下降。
- 逆概率加权估计显示,TMVR后1年54.2%(95%CI 52.2%–56.1%)患者存活且健康良好;23.0%死亡,21.9%持续健康状态差(KCCQ-OS<60分),5.5%健康状态较基线下降,4.6%同时存在健康状态差和下降。
临床怎么用
- TMVR可用于改善重度二尖瓣反流患者症状、功能状态和生活质量,术后30天内即可显现。
- 术前应评估房颤、起搏器、严重肺病、家庭氧疗及基线KCCQ等影响30天健康状态的因素。
- 术后1年需关注死亡及持续健康状态差(KCCQ-OS<60分)的风险。
局限性
- KCCQ数据在基线、30天和1年的可用率分别为81.2%、69.3%和47.4%,存在缺失。
- 1年结局分析基于逆概率加权估计,可能受未测量混杂影响。
- 注册研究设计,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Improvements in symptoms, functional capacity, and quality of life are among the key goals of edge-to-edge transcatheter mitral valve repair (TMVR) for mitral regurgitation. OBJECTIVE: To examine health status outcomes among patients undergoing TMVR in clinical practice and the factors associated with improvement. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, which contains data on patients with severe mitral regurgitation treated with TMVR from 2013 through 2017 in 217 US hospitals. MAIN OUTCOMES AND MEASURES: Change in disease-specific health status (Kansas City Cardiomyopathy Questionnaire-Overall Summary score [KCCQ-OS]; range 0-100 points, with higher scores indicating better health status) at 30 days and 1 year after TMVR. We also examined factors associated with health status at 30 days after TMVR, by means of multivariable linear regression using a generalized estimating equations approach to account for clustering of patients within sites. RESULTS: The KCCQ data were available in 81.2% at baseline, 69.3% of survivors at 30 days, and 47.4% of survivors at 1 year. Among 4226 patients who underwent TMVR, survived 30 days, and completed the KCCQ at baseline and follow-up, the KCCQ-OS increased from 41.9 before TMVR to 66.7 at 30 days (mean change 24.8 [95% CI, 24.0-25.6] points; P < .001), representing a large clinical improvement. The KCCQ scores remained stable from 30 days to 1 year after TMVR, with no further significant increase or decline. On multivariable analysis, atrial fibrillation (-2.2 [95% CI, -3.7 to -0.6] points; P = .01), permanent pacemaker (-2.1 [95% CI, -3.7 to -0.4] points; P = .01), severe lung disease (-3.9 [95% CI, -6.2 to -1.5] points; P = .001), home oxygen (-2.7 [95% CI, -4.9 to -0.4] points; P = .02), and lower KCCQ scores at baseline (3.9 points for each 10-point increase [95% CI, 3.6-4.2]; P < .001) were independently associated with lower 30-day KCCQ-OS scores. In-hospital renal failure was uncommon but was also associated with significant reductions in 30-day KCCQ-OS scores (-7.3 [95% CI -13.3 to -1.2] points). In estimates calculated with inverse probability weighting, after 1 year after TMVR, 54.2% (95% CI 52.2%-56.1%) of patients were alive and well; 23.0% had died, 21.9% had persistently poor health status (KCCQ-OS <60 points), 5.5% had a health status decline from baseline, and 4.6% had both poor health status and health status decline. CONCLUSIONS AND RELEVANCE: In a national cohort of US patients undergoing edge-to-edge TMVR in clinical practice, health status was impaired prior to the procedure, improved within 30 days, and remained stable through 1 year among surviving patients with available data. While long-term mortality remains high, most surviving patients demonstrate improvements in symptoms, functional status, and quality of life, with only modest differences by patient-level factors.
引用
- Arnold SV, Li Z, Vemulapalli S, et al. Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year: Analysis of the Transcatheter Valve Therapy Registry. JAMA Cardiol. 2018. PMID: 30476950. doi:10.1001/jamacardio.2018.3359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。